Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant-Reference-Cited by-同舟云学术

Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant

Published:2022-10-20 Issue:2 Volume:108 Page:615-620
ISSN:1592-8721
Container-title:Haematologica
language:
Short-container-title:haematol

Author:

Chen George,Herr Megan,Nowak Jan,Ho Christine,Almyroudis Nikolaos,Attwood Kristopher,Bonnewell John,Walsh Marissa,Segal Brahm,Ross Maureen,McCarthy Philip,Hahn Theresa

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Reference14 articles.

1. Zuhair M, Smit GSA, Wallis G. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol. 2019; 29(3):e2034.

2. Green ML, Leisenring W, Xie H. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016; 3(3):e119-127.

3. Chen GL, Wallace PK, Zhang Y. Low-Level Cytomegalovirus antigenemia promotes protective cytomegalovirus antigen-specific T cells after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2020; 26(11):2147-2154.

4. Wittmann Dayagi T, Sherman G, Bielorai B. Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells. Leuk Lymphoma. 2021; 62(7):1692-1701.

5. Hill JA, Li D, Hay KA. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018; 131(1):121-130.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS.;Mediterranean Journal of Hematology and Infectious Diseases;2024-08-31

2. Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention;Frontiers in Immunology;2024-08-26

3. Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum;Clinical Infectious Diseases;2024-07-23

4. Cytomegaloviral Infections in Recipients of Chimeric Antigen Receptor T-Cell Therapy: An Observational Study With Focus on Oncologic Outcomes;Open Forum Infectious Diseases;2024-07-18

5. Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy;Blood Advances;2024-07-12